Malignant neoplasm of exocervix
ICD-10 C53.1 is a billable code used to indicate a diagnosis of malignant neoplasm of exocervix.
C53.1 refers to malignant neoplasms located specifically in the exocervix, which is the outer part of the cervix that protrudes into the vagina. This type of cancer is often associated with human papillomavirus (HPV) infection, which is a significant risk factor. Symptoms may include abnormal vaginal bleeding, pelvic pain, and unusual discharge. Diagnosis typically involves a Pap smear followed by a biopsy to confirm malignancy. Staging of cervical cancer is crucial for determining treatment options and prognosis, with the FIGO staging system commonly used. Treatment may involve surgery, radiation, and chemotherapy, depending on the stage of the disease. The CA-125 blood test is not typically used for cervical cancer but may be relevant in cases of ovarian cancer or other gynecological malignancies. Surgical approaches can include conization, hysterectomy, and lymphadenectomy, depending on the extent of the disease. Accurate coding is essential for proper treatment planning and reimbursement.
Detailed pathology reports, treatment plans, and staging information.
Diagnosis and treatment planning for cervical cancer, follow-up care post-surgery.
Ensure accurate documentation of HPV status and staging to support coding.
Radiation treatment plans, imaging studies, and response assessments.
Patients receiving radiation therapy for cervical cancer.
Document the specific radiation techniques used and any side effects experienced by the patient.
Used for surgical treatment of C53.1 when the cancer is localized.
Operative report detailing the procedure and findings.
Ensure the surgical approach is documented clearly.
HPV is a major risk factor for the development of cervical cancer, including malignant neoplasms of the exocervix. Accurate documentation of HPV status is crucial for treatment planning and coding.
